GALNT2

Polypeptide N-acetylgalactosaminyltransferase 2 · Q10471 · GALNT2 on Sugi Atlas →

2,722 patent compounds predicted against GALNT2, 2,123 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ellagic Acid (SCHEMBL20429)	1.00	2/20
Ellagic Acid (SCHEMBL1645767)	1.00	2/20
Ellagic Acid (SCHEMBL177722)	0.96	2/20
Ellagic Acid (SCHEMBL2639621)	0.96	2/20
Ellagic Acid (SCHEMBL2354431)	0.85	2/20
Ellagic Acid (SCHEMBL3801270)	0.82	2/20
Ellagic Acid (SCHEMBL2168301)	0.77	2/20
SCHEMBL2369012	0.77	2/20
Ellagic Acid (SCHEMBL4429252)	0.77	2/20
Ellagic Acid (SCHEMBL2369009)	0.74	2/20
SCHEMBL2355138	0.72	2/20
Ellagic Acid (SCHEMBL3800835)	0.70	2/20
SCHEMBL2357304	0.68	2/20
SCHEMBL2354425	0.66	2/20
Ellagic Acid (SCHEMBL1279506)	0.64	2/20
SCHEMBL1231438	0.62	2/20
Ellagic Acid (SCHEMBL1279897)	0.62	2/20
Ellagic Acid (SCHEMBL2462871)	0.57	2/20
SCHEMBL3661426	0.57	2/20
SCHEMBL2792438	0.55	2/20

Clinical trials — most relevant to GALNT2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease	PHASE4	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study of GlcNAc on Tear Production in NGLY1-CDDG	PHASE2	ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA	PHASE1/PHASE2	COMPLETED
OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease	PHASE2	COMPLETED
Multi-Center Study of ManNAc for GNE Myopathy	PHASE2	ACTIVE_NOT_RECRUITING
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING
BMN 110 US Expanded Access Program	nan	APPROVED_FOR_MARKETING
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease	nan	RECRUITING
Screening of Fabry Disease in Patients With GI Symptoms	nan	UNKNOWN
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Natural History Study of Participants With Sanfilippo Syndrome Type IIIC	nan	RECRUITING
Registry Gangliosidoses	nan	UNKNOWN
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
Italian Anderson Fabry Disease Cardiovascular Registry	nan	RECRUITING
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption	nan	UNKNOWN
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)	nan	RECRUITING
Biomarker for Patients With Fabry Disease (BioFabry)	nan	WITHDRAWN
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a GALNT2 binder may also engage these)

Protein	Name	Similarity
Q6PB93	—	1.000	Q6PB93 →
GALNT10	Polypeptide N-acetylgalactosaminyltransferase 10	0.997	landscape →
O08912	—	0.997	O08912 →
Q925R7	—	0.996	Q925R7 →
Q29121	—	0.996	Q29121 →
Q6WV19	—	0.995	Q6WV19 →
Q8MV48	—	0.995	Q8MV48 →
GALNT13	Polypeptide N-acetylgalactosaminyltransferase 13	0.994	landscape →
Q8CF93	—	0.994	Q8CF93 →
GALNT1	Polypeptide N-acetylgalactosaminyltransferase 1	0.994	landscape →
Q6UE39	—	0.994	Q6UE39 →
Q9JJ61	—	0.994	Q9JJ61 →
Q8IXK2	—	0.994	Q8IXK2 →
Q07537	—	0.994	Q07537 →
S5S833	—	0.993	S5S833 →
Q49A17	—	0.993	Q49A17 →
Q10473	—	0.993	Q10473 →
Q6WV17	—	0.993	Q6WV17 →
Q8N428	—	0.992	Q8N428 →
Q5EA41	—	0.992	Q5EA41 →
Q8MRC9	—	0.992	Q8MRC9 →
Q6P9S7	—	0.991	Q6P9S7 →
Q8BVG5	—	0.991	Q8BVG5 →
Q6DJR8	—	0.991	Q6DJR8 →
Q8C7U7	—	0.990	Q8C7U7 →
Q8I136	—	0.990	Q8I136 →
Q8NCW6	—	0.990	Q8NCW6 →
Q6P6V1	—	0.990	Q6P6V1 →
Q921L8	—	0.989	Q921L8 →
P34678	—	0.989	P34678 →